Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gisa Ellrichmann

Showing results (11-20 of 53) with videos related to

Pageof 6
Sort By:
Therapeutic Advances in Neurological Disorders|October 3, 2017
Bortezomib in severe MuSK-antibody positive myasthenia gravis: first clinical experienceChristiane Schneider-Gold, Anke Reinacher-Schick, Gisa Ellrichmann, et al.
Therapeutic Advances in Neurological Disorders|November 6, 2014
Rituximab postprogressive multifocal leukoencephalopathy: a Feasible therapeutic option in selected casesRobert Hoepner, Simon Faissner, Gisa Ellrichmann, et al.
International Immunopharmacology|June 14, 2012
Anti-inflammatory effects of levetiracetam in experimental autoimmune encephalomyelitisJan Thöne, Gisa Ellrichmann, Pedro M Faustmann, et al.
Frontiers in Neurology|September 21, 2017
Insight into Metabolic <sup>1</sup>H-MRS Changes in Natalizumab Induced Progressive Multifocal Leukoencephalopathy Brain LesionsRuth Schneider, Barbara Bellenberg, Robert Hoepner, et al.
Therapeutic Advances in Neurological Disorders|November 12, 2015
Tumefactive multiple sclerosis lesions in two patients after cessation of fingolimod treatmentSimon Faissner, Robert Hoepner, Carsten Lukas, et al.
Journal of the Neurological Sciences|March 6, 2016
Relevance of endoglin, IL-1α, IL-1β and anti-ovarian antibodies in females with multiple sclerosisJan Thöne, Ingo Kleiter, Anna Stahl, et al.
Therapeutic Advances in Neurological Disorders|April 7, 2017
Two years' long-term follow up in chronic inflammatory demyelinating polyradiculoneuropathy: efficacy of intravenous immunoglobulin treatmentGisa Ellrichmann, Ralf Gold, Ilya Ayzenberg, et al.
Brain & Spine|May 23, 2023
Subarachnoid hemorrhages and aneurysms during the SARS-CoV2-pandemia at a tertiary medical center - Analysis of incidence and outcomeKonstantinos Lintas, Stefan Rohde, Gisa Ellrichmann, et al.
Blood Purification|September 16, 2020
Successful Treatment of Severe Digitoxin Intoxication with CytoSorb® HemoadsorptionThomas Georg Karl Breuer, Daniel Robert Quast, Stephan Wiciok, et al.
Therapeutic Advances in Neurological Disorders|October 25, 2014
Fumarate treatment in progressive forms of multiple sclerosis: first results of a single-center observational studyKatrin Strassburger-Krogias, Gisa Ellrichmann, Christos Krogias, et al.
Pageof 6

Showing results (11-20 of 53) with videos related to

Sort By:
Pageof 6
Therapeutic Advances in Neurological Disorders|October 3, 2017
Bortezomib in severe MuSK-antibody positive myasthenia gravis: first clinical experienceChristiane Schneider-Gold, Anke Reinacher-Schick, Gisa Ellrichmann, et al.
Therapeutic Advances in Neurological Disorders|November 6, 2014
Rituximab postprogressive multifocal leukoencephalopathy: a Feasible therapeutic option in selected casesRobert Hoepner, Simon Faissner, Gisa Ellrichmann, et al.
International Immunopharmacology|June 14, 2012
Anti-inflammatory effects of levetiracetam in experimental autoimmune encephalomyelitisJan Thöne, Gisa Ellrichmann, Pedro M Faustmann, et al.
Frontiers in Neurology|September 21, 2017
Insight into Metabolic <sup>1</sup>H-MRS Changes in Natalizumab Induced Progressive Multifocal Leukoencephalopathy Brain LesionsRuth Schneider, Barbara Bellenberg, Robert Hoepner, et al.
Therapeutic Advances in Neurological Disorders|November 12, 2015
Tumefactive multiple sclerosis lesions in two patients after cessation of fingolimod treatmentSimon Faissner, Robert Hoepner, Carsten Lukas, et al.
Journal of the Neurological Sciences|March 6, 2016
Relevance of endoglin, IL-1α, IL-1β and anti-ovarian antibodies in females with multiple sclerosisJan Thöne, Ingo Kleiter, Anna Stahl, et al.
Therapeutic Advances in Neurological Disorders|April 7, 2017
Two years' long-term follow up in chronic inflammatory demyelinating polyradiculoneuropathy: efficacy of intravenous immunoglobulin treatmentGisa Ellrichmann, Ralf Gold, Ilya Ayzenberg, et al.
Brain & Spine|May 23, 2023
Subarachnoid hemorrhages and aneurysms during the SARS-CoV2-pandemia at a tertiary medical center - Analysis of incidence and outcomeKonstantinos Lintas, Stefan Rohde, Gisa Ellrichmann, et al.
Blood Purification|September 16, 2020
Successful Treatment of Severe Digitoxin Intoxication with CytoSorb® HemoadsorptionThomas Georg Karl Breuer, Daniel Robert Quast, Stephan Wiciok, et al.
Therapeutic Advances in Neurological Disorders|October 25, 2014
Fumarate treatment in progressive forms of multiple sclerosis: first results of a single-center observational studyKatrin Strassburger-Krogias, Gisa Ellrichmann, Christos Krogias, et al.
Pageof 6